National Blood Clot Alliance (NBCA) Designates Two AdventHealth Hospitals as Centers of Excellence for VTE Care
'I am immensely proud of the work we have done in VTE treatment and intervention, and very grateful for the recognition that this COE represents.'— Dr. Arkadiy Kheyfits, AdventHealth Palm Coast and Palm Coast Parkway
PALM COAST, FL, UNITED STATES, May 15, 2025 / EINPresswire.com / -- The National Blood Clot Alliance (NBCA) is proud to announce the designation of AdventHealth Palm Coast and AdventHealth Palm Coast Parkway as NBCA Venous Thromboembolism (VTE) Centers of Excellence™. These hospitals are the first in the AdventHealth system and the first in Northeast Florida to earn this prestigious recognition for their commitment to delivering exceptional, patient-centered care in the prevention, diagnosis, and treatment of blood clots.
Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), remains a significant public health concern in the United States. According to the Centers for Disease Control and Prevention (CDC), up to 900,000 people in the U.S. are affected by VTE each year, and as many as 100,000 die as a result. Despite these alarming numbers, VTE remains underdiagnosed and undertreated—highlighting the importance of comprehensive, multidisciplinary approaches to care.
'I am immensely proud of the work we have done in VTE treatment and intervention, and very grateful for the recognition that this COE represents' said Dr. Arkadiy Kheyfits, Interventional Radiologist at AdventHealth Palm Coast and Palm Coast Parkway.' I believe AdventHealth Palm Coast and Palm Coast Parkway are leaders in this space, and I am excited to continue improving our care and prevention pathways.'
As NBCA VTE Centers of Excellence™, both AdventHealth Palm Coast campuses join a growing network of leading institutions recognized for advancing VTE care through clinical excellence, innovation, and a commitment to education and prevention. This expanding network includes distinguished centers such as Corewell Health West Butterworth Hospital in Grand Rapids, MI, and Ascension Sacred Heart Hospital in Pensacola, FL.
'NBCA VTE Centers of Excellence™ are setting a new standard in how we approach VTE—from acute management to long-term prevention,' said Erin VanDyke, PA-C, Vice President of the NBCA COE Program. 'The teams at AdventHealth Palm Coast and Palm Coast Parkway exemplify the mission of this program through their multidisciplinary collaboration, dedication to best practices, and focus on patient outcomes. We are proud to welcome them as the first designated Centers of Excellence in both the AdventHealth system and Northeast Florida.'
The NBCA COE program aims to improve outcomes and save lives by partnering with institutions that embrace innovative, evidence-based, and patient-focused strategies to prevent and treat VTE.
To learn more about the NBCA VTE Centers of Excellence™ program, visit stoptheclot.org.
About the National Blood Clot Alliance (NBCA)
Established in 2003, the National Blood Clot Alliance (NBCA) is the nation's leading nonprofit, patient advocacy organization dedicated to advancing the prevention, early diagnosis, and treatment of life-threatening blood clots. Through a strategic focus on education, advocacy, and research, NBCA empowers patients and families, supports healthcare professionals, and drives national efforts to improve awareness, detection, and outcomes related to VTE. NBCA leads initiatives that strengthen the standard of care and foster innovation in VTE prevention and treatment across the United States.
About AdventHealth
AdventHealth is a connected network of care that helps people feel whole – body, mind and spirit. More than 100,000 team members across a national footprint provide whole-person care to nearly nine million people annually through more than 2,000 care sites that include hospitals, physician practices, ambulatory surgery centers, outpatient clinics, home health agencies, hospice centers, the AdventHealth app and more. Our wholistic approach to improving the health and prosperity of our communities is inspired by our mission to extend the healing ministry of Christ. For the latest news about AdventHealth, visit AdventHealth.com/news.
Tarin Patrikis
National Blood Clot Alliance
[email protected]
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
19 minutes ago
- Business Wire
From Seattle to Chiba: Okayama University Taps AGC Biologics' Global Pathway for New Therapeutic
SEATTLE & CHIBA, Japan--(BUSINESS WIRE)--AGC Biologics, your friendly CDMO expert, today announced a new service agreement with Okayama University, a prominent national university in Japan. This project will leverage AGC Biologics' global network, with the mammalian cell line development capabilities in Seattle, USA, and cGMP mammalian manufacturing facility in Chiba, Japan, working together to advance a new therapeutic program for the university. Under the agreement, AGC Biologics will perform cell line development with its proprietary CHEF1™ expression platform in Seattle. CHEF1's track record includes the production of more than 55 different molecules and the development of five commercial products brought to market. The program will then be transferred to the company's facility in Chiba for process development for clinical trials in 2026. The collaboration between its Asian and U.S. sites highlights AGC Biologics' ability to offer research institutions a seamless, global pathway from early-stage development to clinical manufacturing. 'This project is a perfect example of our winning global blend, combining the world-class cell line development excellence in Seattle with the most-advanced cGMP-compliant mammalian cell culture manufacturing capabilities available in Japan,' said Susumu Zen-in, General Manager of AGC Biologics' Chiba facility. 'By providing a high level of global standard expertise and an emphasis on flexibility, we're able to effectively serve prestigious academic institutions like Okayama University working to bring vital new medicines to patients.' Okayama University selected AGC Biologics for its integrated global network and its unique position in Japan. The Chiba facility offers mammalian cell culture-based services to serve the needs of customers from Japan and the surrounding regions. This partnership underscores AGC Biologics' commitment to supporting academic and research institutions by providing the technical creativity and specialized services needed to solve complex challenges and advance important new therapies. To learn more about AGC Biologics' global network of services, visit About AGC Biologics AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, to provide friendly and expert services. We provide world-class development and manufacturing of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with locations in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba and Yokohama, Japan. We currently employ more than 2,600 Team Members worldwide. AGC Biologics is a part of AGC Inc.'s Life Science Business. The Life Science Business runs 10+ facilities focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. To learn more, visit
Health Line
5 hours ago
- Health Line
Types of Atrial Fibrillation: What You Need to Know
Key takeaways AFib is classified into four types based on how long the irregular heartbeat lasts: paroxysmal, persistent, long-standing persistent, and permanent. Paroxysmal AFib comes and goes on its own, while persistent AFib lasts longer and may require medical intervention. Long-standing persistent AFib lasts for at least a year, and permanent AFib is continuous. Treatment options vary depending on the type of AFib, but the goals are to restore normal heart rhythm, manage heart rate, and prevent blood clots. Overview Atrial fibrillation (AFib) is a type of arrhythmia, or irregular heartbeat. It causes the upper and lower chambers of your heart to beat out of sync, fast, and erratically. AFib used to be classified as either chronic or acute. But in 2014, new guidelines from the American College of Cardiology and American Heart Association changed the classification of atrial fibrillation from two types to four: paroxysmal AFib persistent AFib long-standing persistent AFib permanent AFib You can start with one type of AFib that eventually becomes another type as the condition progresses. Keep reading to learn more about each type. 1. Paroxysmal atrial fibrillation Paroxysmal AFib comes and goes. It begins and ends spontaneously. The irregular heartbeat may last anywhere from several seconds to a week. However, most episodes of paroxysmal AFib resolve themselves within 24 hours. Paroxysmal AFib may be asymptomatic, which means that you experience no apparent symptoms. The first line of treatment for asymptomatic paroxysmal AFib may be lifestyle changes, such as reducing daily caffeine consumption and reducing stress, in addition to medications as preventative measures. 2. Persistent atrial fibrillation Persistent AFib also begins spontaneously. It lasts at least seven days and may or may not end on its own. Medical intervention such as cardioversion, in which your doctor shocks your heart into rhythm, may be needed to stop an acute, persistent AFib episode. Lifestyle changes and medications may be used as preventive measures. 3. Long-standing persistent atrial fibrillation Long-standing persistent AFib lasts at least a year without interruption. It's often associated with structural heart damage. This type of AFib can be the most challenging to treat. Medications to maintain a normal heart rate or rhythm are often ineffective. More invasive treatments may be needed. These can include: electrical cardioversion catheter ablation pacemaker implantation 4. Permanent atrial fibrillation Long-standing persistent AFib can become permanent when treatment doesn't restore normal heart rate or rhythm. As a result, you and your doctor make a decision to stop further treatment efforts. This means your heart is in a state of AFib all the time. According to research, this type of AFib may result in more severe symptoms, lower quality of life, and an increased risk of a major cardiac event.
Yahoo
7 hours ago
- Yahoo
Arthrex NanoScope™ System Receives Pediatric Clearance for Orthopedic, Laparoscopic Procedures
NAPLES, Fla., July 16, 2025 /PRNewswire/ -- Arthrex, a global leader in minimally invasive surgical technology, announced that it has received U.S. Food and Drug Administration (FDA) clearance to use the Arthrex NanoScope™ operative arthroscopy system for pediatric orthopedics and laparoscopy. The NanoScope system is a compact, high-resolution mobile imaging platform featuring the industry's first high-definition, chip-on-tip camera — known as the NanoNeedle Scope — engineered specifically to meet the unique anatomical and procedural needs of pediatric patients. "This innovative and disruptive technology is transforming the way we approach diagnostic and least-invasive surgical treatments, and we are extremely proud to expand its indications to the field of pediatric orthopedics and laparoscopy," said Arthrex President and Founder Reinhold Schmieding. The NanoScope system can be used in common pediatric cases like general knee arthroscopy, meniscal treatments, anterior cruciate ligament (ACL) reconstruction, general shoulder arthroscopy and hernia or diagnostic laparoscopy in the abdomen. The smaller scope is designed to minimize the potential risk of damaging anatomical structures upon entry along with neurovascular structures. "FDA clearance for use of the NanoScope system in pediatric patients is an important, exciting step forward," said J. Lee Pace, MD. "Its smaller size makes it ideal for navigating pediatric joints while still delivering excellent image quality for routine or even more complex cases." Most Nano arthroscopy procedures can be performed outside of a traditional operating room, such as in a physician's office or an ambulatory surgery center, offering a more convenient and flexible option for both diagnosis and treatment. Patients and doctors can also discuss anesthesia options to determine the level that best fits a particular procedure and the patient's comfort level, from local anesthesia — allowing the patient to stay awake during treatment — to twilight anesthesia, or mild sedation. This minimally invasive approach also means a smaller scar,1 less risk of infection2 and the potential for less pain, reducing the need for prescriptive pain medications.3 To learn more about Nano arthroscopy, visit For more information, downloadable multimedia assets and interview requests for subject matter experts, contact Arthrex Media Relations at media@ About Arthrex Arthrex, headquartered in Naples, Florida, is a global medical device company and leader in multispecialty minimally invasive surgical technology innovation, scientific research, manufacturing and medical education. The company has pioneered the field of arthroscopy and sports medicine and develops more than 1,000 new products and related procedures annually to advance minimally invasive orthopedic surgery, trauma, spine, cardiothoracic, orthobiologics and arthroplasty innovation worldwide. Arthrex also specializes in the latest 4K multispecialty surgical visualization and OR integration technology solutions. For more information, visit Physician is a paid consultant of Arthrex, Inc. References Schaver AL, Lash JG, MacAskill ML, et al. Partial meniscectomy using needle arthroscopy associated with significantly less pain and improved patient reported outcomes at two weeks after surgery: a comparison to standard knee arthroscopy. J Orthop. 2023;41:63-66. doi:10.1016/ McMillan S, Chhabra A, Hassebrock JD, Ford E, Amin NH. Risks and complications associated with intra-articular arthroscopy of the knee and shoulder in an office setting. Orthop J Sports Med. 2019;7(9):2325967119869846. doi:10.1177/2325967119869846 Bradsell H, Lencioni A, Shinsako K, Frank RM. In-office diagnostic needle arthroscopy using the NanoScope™ arthroscopy system. Arthrosc Tech. 2022;11(11):e1923-e1927. doi:10.1016/ View original content to download multimedia: SOURCE Arthrex, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
